NVCR News and Press, NovoCure Limited From 07/29/21

NovoCure Limited (NVCR) Q2 2021 Earnings Conference Call July 29, 2021 08:00 AM ET Company Participants Ingrid Goldberg - Vice President Finance & Investor Relations Bill Doyle - Executive Chairman Asaf Danziger - Chief Executive Officer Ashley Cordova - Chief Financial Officer Uri Weinbe...

NovoCure (NASDAQ:NVCR) shares slide more than 4% premarket after the company posted second-quarter results that missed Wall Street estimates, hurt my a rise in research and development expenses during the period. Quarterly revenue rose 15% to $133.5M, but fell short of analysts' ave...

NovoCure (NASDAQ:NVCR): Q2 GAAP EPS of -$0.14 misses by $0.15. Revenue of $133.5M (+15.2% Y/Y) misses by $8.34M. Quarterly net revenues of $133.5 million, presenting 15% growth versus the second quarter of 2020 with 79% gross margin. There were 3,487 active patients at June 30, 2021, represen...

Quarterly net revenues of $133.5 million, presenting 15% growth versus the second quarter of 2020 with 79% gross margin Invested record $50 million in research and development initiatives across brain, thoracic and abdominal programs Novocure (NASDAQ: NVCR) today rep...

Awards totaling more than $2 million aim to promote and support innovative research on Tumor Treating Fields to deepen understanding and accelerate the development of new treatment strategies Novocure (NASDAQ: NVCR) today announced the recipients of the 3rd Annual AACR-Novoc...

Stocks with the highest sales growth rates have been among the very top performers in recent years, albeit with plenty of volatility included. However, the group is showing weakness in recent trading sessions, and the media’s fear-mongering narratives (about this being the star...

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2021 on Thursday, July 29, 2021, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the thr...

Matteo Colombo/DigitalVision via Getty Images S&P 500 Health Care Sector Index rose ~2.0% over the week to outpace the ~1.7% gain in the S&P 500 as gene editing companies rallied after Intellia (NTLA) and Regeneron (REGN) showed promise in the CRISPR technology with fir...

NovoCure is an attractive, high-growth, oncology company with a large market opportunity. The shares are particularly volatile following yesterday's liver cancer study results, which has created an attractive high-income options trade opportunity. We believe this is an attractive ...

Mario13/E+ via Getty Images Arcturus wins new bullish call at Cantor on experimental COVID-19 shot Arcturus Therapeutics (ARCT) has added ~1.3% in the pre-market after Cantor Fitzgerald initiated its coverage with an overweight recommendation highlighting the company’s effort...